Description of infections (grade 3 or higher) occurring during CPX-351 therapy
| Site . | Type of germ . | Grade ≥3 . |
|---|---|---|
| Blood | Gram-positive cocci, gram-negative bacilli | 25 (24) |
| Lung | Aspergillus, gram-positive cocci | 30 (30) |
| Urinary tract | Gram-negative bacilli | 8 (8) |
| Gastrointestinal tract | Gram-negative bacilli, Clostridium | 6 (6) |
| ENT region | — | 4 (5) |
| Catheter | Gram-positive cocci | 4 (2) |
| Skin | Gram-positive cocci | 2 (2) |
| Reproductive tract | — | 1 (1) |
| Liver | Candida | 1 (1) |
| Unknown | Gram-positive cocci, gram-negative bacilli | 44 (43) |
| Site . | Type of germ . | Grade ≥3 . |
|---|---|---|
| Blood | Gram-positive cocci, gram-negative bacilli | 25 (24) |
| Lung | Aspergillus, gram-positive cocci | 30 (30) |
| Urinary tract | Gram-negative bacilli | 8 (8) |
| Gastrointestinal tract | Gram-negative bacilli, Clostridium | 6 (6) |
| ENT region | — | 4 (5) |
| Catheter | Gram-positive cocci | 4 (2) |
| Skin | Gram-positive cocci | 2 (2) |
| Reproductive tract | — | 1 (1) |
| Liver | Candida | 1 (1) |
| Unknown | Gram-positive cocci, gram-negative bacilli | 44 (43) |
Values represent n (%) of patients.
ENT, ear, nose, and throat.